Pharmacologically targeting c-KIT provides a golden opportunity to investigate the differential effects of these compounds in AD, PD, ALS, and frontotemporal dementia (FTD), as well as mast cell disease with c-KIT mutations (mastocystosis) and without (psoriasis and urticaria) c-KIT mutations. Here, KIT is linked to urticaria.